Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL Clinical Trials
2 recruitingDrug
Phase 42
Showing 1–2 of 2 trials
Recruiting
Phase 4
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary InterventionPeripheral Endovascular Intervention
Duke University6,000 enrolled78 locationsNCT06909565
Recruiting
Phase 4
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
University of California, San Diego100 enrolled1 locationNCT06865885